GSK and other drugmakers fending off litigation claiming that gastrointestinal drug Zantac or a generic caused cancer have won a supreme court ruling in Canada, after also chalking up wins in the US.

Some Delaware Supreme Court justices signaled they may be skeptical of a bid by GSK Plc ... lawsuits to proceed to trial over claims that the heartburn drug Zantac is linked to cancer.

who did not know that GSK had for decades concealed an internal study that implicated the Company's liability to Zantac users; and (4) as a result, Defendants' positive statements about the ...

GSK plc (NYSE:GSK) met the main goal in a late-stage trial of linerixibat, a treatment for cholestatic pruritus, a severe itching condition caused by an autoimmune liver disease called ...

Zantac was prescribed over 15 million times annually after being introduced in the United States in 1983. The Ohio AG’s office claims that GSK and its predecessor company hit an internal study ...

CASE DETAILS: According to the filed complaint, defendants represented to investors that GSK removed Zantac from the market "[b]ased on information available at the time and correspondence with ...

who did not know that GSK had for decades concealed an internal study that implicated the Company's liability to Zantac users; and (4) as a result, Defendants' positive statements about the ...

GSK has reported positive outcomes from the randomised Phase III GLISTEN trial of the targeted inhibitor of ileal bile acid transporter (IBAT), linerixibat. The therapy aims to treat adults with ...

who did not know that GSK had for decades concealed an internal study that implicated GSK's liability to Zantac users. When the true details entered the market, the lawsuit claims that investors ...